Is dystonia scored on the Abnormal Involuntary Movement Scale (AIMS)?

Is Dystonia Scored on the AIMS Exam?

No, the AIMS (Abnormal Involuntary Movement Scale) was designed primarily to assess tardive dyskinesia, not dystonia, though dystonia may be incidentally observed during the examination.

Understanding the AIMS Design and Limitations

The AIMS was specifically developed to monitor tardive dyskinesia (TD), which consists of athetoid or choreic movements, particularly in the orofacial region 1. The scale focuses on the anatomic distribution and severity of involuntary movements without detailed regard to movement phenomenology 2. This design limitation means the AIMS does not adequately capture or score dystonic movements, which are characterized by slow movements along the long axis of the body culminating in spasms 1.

What the Evidence Shows

Tardive Dystonia vs. Tardive Dyskinesia

While tardive dystonia and tardive dyskinesia can co-occur and both result from antipsychotic exposure, they are distinct entities 1:

• Tardive dyskinesia: Choreic/athetoid movements (what AIMS measures)
• Tardive dystonia: Sustained muscle contractions and spasms (not adequately captured by AIMS)

The guidelines explicitly state that "the same strategies for treating tardive dyskinesia should be used for tardive dystonia" 1, but this does not mean the AIMS adequately measures dystonia.

Research Using AIMS for Dystonia

Some research studies have used the AIMS to assess dystonia 3, 4, 5, but this represents an off-label application of the scale. These studies acknowledge the AIMS was not designed for dystonia assessment. For example, one study used both the AIMS and the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) together, recognizing that AIMS alone was insufficient for dystonia 5.

The Better Alternative

For dystonia assessment, use the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) or the Extrapyramidal Symptom Rating Scale (ESRS) 5, 6. The ESRS specifically assesses four types of drug-induced movement disorders including dystonia, parkinsonism, akathisia, and tardive dyskinesia, with validated clinimetric properties 6.

Clinical Pitfalls to Avoid

1. Don't assume AIMS captures all movement disorders: The AIMS focuses on dyskinetic movements and will miss or underestimate dystonic features
2. Don't confuse co-occurrence with adequate measurement: Just because tardive dystonia often occurs with tardive dyskinesia doesn't mean AIMS measures both equally
3. Recognize the need for updated tools: Current literature acknowledges that AIMS has "clinimetric limitations" and calls for revision to incorporate broader phenomenologic assessment 2

Practical Recommendation

When monitoring patients on antipsychotics:

• Use AIMS for tardive dyskinesia screening (as recommended every 3-6 months) 1
• Add ESRS or BFMDRS if dystonia is suspected or present to capture the full spectrum of movement abnormalities 5, 6
• Document dystonic features separately in clinical notes, as they may require different management approaches